Evidence map›Paper›PMID 22747522›Full record

ArticleImmunology2012

Loss in CD4 T-cell responses to multiple epitopes in influenza due to expression of one additional MHC class II molecule in the host.

Jennifer L Nayak, Andrea J Sant

Open access · greenAbstract read
In one paragraph

Article in Immunology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.3field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Protein Vaccination Directs the CD4Journal of virology · 2019
    Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Jennifer L NayakDepartment of Pediatrics, University of Rochester Medical Center, Rochester, NY 14642, USA. jennifer_nayak@urmc.rochester.edu
Andrea J Sant
University of Rochester Medical Center · US

Funding

Immunodominance in CD4 T Cell ResponsesR01AI051542 · NIAID · UNIVERSITY OF ROCHESTER · PI SANT, ANDREA JANINE · 2002 to 2012
$3.6M
TRAINING IN PEDIATRIC INFECTIOUS DISEASEST32AI007464 · NIAID · UNIVERSITY OF ROCHESTER · PI GIGLIOTTI, FRANCIS · 1995 to 2014
$2.2M
Translational Molecular Pediatric ResearchK12HD068373 · NICHD · UNIVERSITY OF ROCHESTER · PI SCHOR, NINA F · 2011 to 2015
$2.0M
Manipulation of immunodominance to promote heterosubtypic immunity to InfluenzaR21AI069372 · NIAID · UNIVERSITY OF ROCHESTER · PI SANT, ANDREA JANINE · 2006 to 2007
$423k
NIAID NIH HHS HHSN266200700008CNIAID NIH HHS R01 AI051542NIAID NIH HHS R21 AI069372NIAID NIH HHS T32 AI007464NICHD NIH HHS 1K12HD068373-01NICHD NIH HHS K12 HD068373
6 · The paper itself

Abstract

An understanding of factors controlling CD4 T-cell immunodominance is needed to pursue CD4 T-cell epitope-driven vaccine design, yet our understanding of this in humans is limited by the complexity of potential MHC class II molecule expression. In the studies described here, we took advantage of genetically restricted, well-defined mouse strains to better understand the effect of increasing MHC class II molecule diversity on the CD4 T-cell repertoire and the resulting anti-influenza immunodominance hierarchy. Interferon-γ ELISPOT assays were implemented to directly quantify CD4 T-cell responses to I-A(b) and I-A(s) restricted peptide epitopes following primary influenza virus infection in parental and F(1) hybrid strains. We found striking and asymmetric declines in the magnitude of many peptide-specific responses in F(1) animals. These declines could not be accounted for by the lower surface density of MHC class II on the cell or by antigen-presenting cells failing to stimulate T cells with lower avidity T-cell receptors. Given the large diversity of MHC class II expressed in humans, these findings have important implications for the rational design of peptide-based vaccines that are based on the premise that CD4 T-cell epitope specificity can be predicted by a simple cataloguing of an individual's MHC class II genotype.

Indexed as

AnimalsAntigen-Presenting CellsCD4-Positive T-LymphocytesEpitopes, T-LymphocyteHistocompatibility Antigens Class IIHumansImmunodominant EpitopesInfluenza A Virus, H1N1 SubtypeInfluenza, HumanInfluenza VaccinesInterferon-gammaMiceMice, Inbred C57BLOrthomyxoviridae InfectionsEpitopes, T-LymphocyteHistocompatibility Antigens Class IIImmunodominant EpitopesInfluenza VaccinesInterferon-gamma

Identifiers

PMID22747522
PMCPMC3401981
OpenAlexW1864338461

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.